LOCALIZED SCLERODERMA - RESPONSE TO 1,25-DIHYDROXYVITAMIN-D3

被引:24
|
作者
HUMBERT, PG
DUPOND, JL
ROCHEFORT, A
VASSELET, R
LUCAS, A
LAURENT, R
AGACHE, P
机构
[1] Department of Dermatology, Centre Hospitalier, Universitaire St-Jacques, Besançon
关键词
D O I
10.1111/j.1365-2230.1990.tb02127.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
1,25‐Dihydroxyvitamin D3 [1,25(OH)2 D3] may be an immunomodulatory drug which could have a role in controlling collagen deposition, and inducing reversal of fibrosis in some tissues. These observations prompted a study of the possible use of this hormone for the treatment of scleroderma. A 35‐year‐old woman, who had been suffering from localized scleroderma for 2 years, was given oral 1,25(OH) 2 D3 for 6 months. The effects of the treatment were evaluated using clinical and physical measurements (skin thickness, extensibility properties of the skin). The evolution of the patient's condition during the 6‐month therapy suggests that 1,25(OH)2 D3 is beneficial in localized scleroderma. The mechanisms of action are discussed in relation to the literature, which suggests both immunoregulatory and inhibitory effects on fibroblast growth. Copyright © 1990, Wiley Blackwell. All rights reserved
引用
收藏
页码:396 / 398
页数:3
相关论文
共 50 条
  • [41] 1,25-DIHYDROXYVITAMIN-D3 AND THE IMMUNE-SYSTEM
    MANOLAGAS, SC
    HUSTMYER, FG
    YU, XP
    PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, 1989, 191 (03): : 238 - 245
  • [42] A SENSITIVE AND SIMPLIFIED RADIOIMMUNOASSAY FOR 1,25-DIHYDROXYVITAMIN-D3
    SCHARLA, S
    SCHMIDTGAYK, H
    REICHEL, H
    MAYER, E
    CLINICA CHIMICA ACTA, 1984, 142 (03) : 325 - 338
  • [43] ORAL 1,25-DIHYDROXYVITAMIN-D3 MINIPULSE THERAPY
    OKADA, K
    KINOSHITA, Y
    TAKAHASHI, S
    NEPHRON, 1994, 67 (01): : 121 - 122
  • [44] PHARMACOKINETICS AND PHARMACODYNAMICS OF 1,25-DIHYDROXYVITAMIN-D3 IN THE CHICK
    BIKLE, DD
    PECK, CC
    HOLFORD, NHG
    ZOLOCK, DT
    MORRISSEY, RL
    ENDOCRINOLOGY, 1982, 111 (03) : 939 - 946
  • [45] INHIBITION OF TROPOELASTIN EXPRESSION BY 1,25-DIHYDROXYVITAMIN-D3
    HINEK, A
    BOTNEY, MD
    MECHAM, RP
    PARKS, WC
    CONNECTIVE TISSUE RESEARCH, 1991, 26 (03) : 155 - 166
  • [46] TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH 1,25-DIHYDROXYVITAMIN-D3
    TILYARD, MW
    OSTEOPOROSIS INTERNATIONAL, 1993, 3 : S194 - S195
  • [47] AFFINITY LABELING OF 1,25-DIHYDROXYVITAMIN-D3 RECEPTOR
    RAY, R
    RAY, S
    MACDONALD, PN
    HAUSSLER, MR
    HOLICK, MF
    JOURNAL OF BONE AND MINERAL RESEARCH, 1992, 7 : S169 - S169
  • [48] THE OVARY - A TARGET ORGAN FOR 1,25-DIHYDROXYVITAMIN-D3
    DOKOH, S
    DONALDSON, CA
    MARION, SL
    PIKE, JW
    HAUSSLER, MR
    ENDOCRINOLOGY, 1983, 112 (01) : 200 - 206
  • [49] INFLUENCE OF THE VITAMIN-D-BINDING PROTEIN ON THE SERUM CONCENTRATION OF 1,25-DIHYDROXYVITAMIN-D3 - SIGNIFICANCE OF THE FREE 1,25-DIHYDROXYVITAMIN-D3 CONCENTRATION
    BOUILLON, R
    VANASSCHE, FA
    VANBAELEN, H
    HEYNS, W
    DEMOOR, P
    JOURNAL OF CLINICAL INVESTIGATION, 1981, 67 (03): : 589 - 596
  • [50] EFFECTS OF CONTINUOUS ADMINISTRATION OF 1,25-DIHYDROXYVITAMIN-D3 ON PLASMA MINERALS AND UNOCCUPIED COLON MUCOSAL 1,25-DIHYDROXYVITAMIN-D3 RECEPTOR CONCENTRATIONS
    NAITO, Y
    GOFF, JP
    HORST, RL
    REINHARDT, TA
    JOURNAL OF DAIRY SCIENCE, 1989, 72 (11) : 2936 - 2941